TORONTO, Ontario and CAMBRIDGE, Mass. – December 2, 2021 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce shareholders passed the share consolidation resolution at its special general meeting of shareholders (the “Special Meeting”) held on December 1, 2021.  With the successful passing of the share consolidation special resolution, the Board of Directors is now authorize ..read more

For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. TORONTO, Ontario and CAMBRIDGE, Mass. – November 17, 2021 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), is pleased to announce that a second independent, third party proxy advisory firm, Institutional Shareholder Services (“ISS”), has recommended that shareholders vote FOR the share consolidation at the upcoming special general meeting of shareholders (the “Special Meeting”) to be h ..read more

TORONTO, Ontario and CAMBRIDGE, Massachusetts – November 12, 2021 – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2021. “We are pleased to be ramping up our efforts to advance our lead asset, PMN 310, closer toward the clinic,” said Gene Williams, ProMIS’ Chairman and CEO. “The financ ..read more

..read more

For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. TORONTO, Ontario and CAMBRIDGE, Mass. – November 2, 2021 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), is pleased to announce that Glass Lewis & Co., LLC (“Glass Lewis”), an independent proxy advisory firm, has recommended that shareholders vote FOR the share consolidation at the upcoming special general meeting of shareholders (the “Special Meeting”) to be held on December 1, 2 ..read more

TORONTO, Ontario and CAMBRIDGE, Massachusetts – Oct 22, 2021– ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Maggie Shafmaster, PhD, JD, to its Board of Directors with immediate effect.  “I am delighted to welcome Maggie Shafmaster as a member of the ProMIS Board of Directors at this time”, said Eugene Williams, Executive Chairman of ProMIS Neurosciences. “Magg ..read more

Expanded management team to lead development programs with special focus on PMN310 for Alzheimer’s disease TORONTO, Ontario and CAMBRIDGE, Massachusetts – Oct 22, 2021– ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced several updates to its senior management team. Eugene Williams, Executive Chairman, will take on the role of Chairman and CEO, with immediate effect. As announced in March ..read more

For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com.  TORONTO, Ontario and CAMBRIDGE, Mass. – October 21, 2021 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that, further to its news release of October 7, 2021, it is filing today on S ..read more

TORONTO, Ontario and CAMBRIDGE, Mass. – October 7, 2021 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that it will hold a special general meeting of shareholders (the “Special Meeting”) on December 1, 2021. The Company has set October 18, 2021, as the record date for the Special Meeting. The purpose of the Special Meeting is to ask shareholders to grant the Board of Direct ..read more

TORONTO, Ontario and CAMBRIDGE, Mass. — September 15, 2021 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Second Annual Undruggable Leaders Forum, a virtual event to be held on September 15-16. ProMIS Chief Development Officer, Dr. Johanne Kaplan, will be presenting her talk entitled “Selective Targeting of Misfolded Pathogenic Proteins in Neurodegenerative Diseases” on ..read more